Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac

Annals of Neurology

Volumn 44, Issue 6, 1998, Pages 942-947

  Lehky, Tanya J ^a,b,g   Levin, Michael C ^a,e   Kubota, Ryuji ^a   Bamford, Richard N ^c   Flerlage, Alfred N ^a   Soldan, Samantha S ^a   Leist, Thomas P ^a   Xavier, Andrew ^a,b   White, Jeffrey D ^c   Brown, Margaret ^d   Fleisher, Thomas A ^d   Top, Lois E ^c   Light, Susan ^f   McFarland, Henry F ^a   Waldmann, Thomas A ^c   Jacobson, Steven ^a  

^a Natl Inst Neurol Disord Stroke

^b Natl Inst Allerg and Infect Dis

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f HOFFMANN LA ROCHE INC   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR ANTIBODY; VIRUS DNA;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAPLEGIA; PRIORITY JOURNAL; SPASTICITY; SPINAL CORD DISEASE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

EID: 0031770389     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440613     Document Type: Article

References (30)

1. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;2:407-410
2. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986;2:1031-1032
3. Poisez BJ, Ruscetti FW, Gazdar AR, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Nad Acad Sci USA 1980;77:7415-7419
4. Jacobson S, Raine CS, Mingioli ES, McFarlin DE. Isolation of an HTLV-I-like retrovirus from patients with tropical spastic paraparesis. Nature 1988;331:540-543
5. Lehky TJ, Fox CH, Koenig S, et al. Detection of human T-lymphotropic virus type I (HTLV-I) tax RNA in the central nervous system of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by in situ hybridization. Ann Neurol 1995;37:167-175
6. Kira J, Itoyama Y, Koyanagi Y, et al. Presence of HTLV-I pro-viral DNA in central nervous system of patients with HTLV-I-associated myelopathy. Ann Neurol 1992;31:39-45
7. x-III) regulators are required for the expression and replication of human T cell leukemia virus type I Genes. Proc Natl Acad Sci USA 1987;84:3653-3657
8. Inoue J, Seiki M, Taniguchi T, et al. Induction of interleukin 2 receptor gene expression by p40x encoded by human T cell leukemia virus type I. EMBO J 1986;5:2883-2888
9. Marcon L, Greenberg SJ, Nelson DL, et al. Soluble interleukin 2 receptor in human T cell leukemia virus type I infections: distinctions between tropical spastic paraparesis and adult T cell leukemia. Clin Res 1988;36:443A (Abstract)
10. Jacobson S, Zaninovic V, Mora C, et al. Immunological findings in neurological diseases associated with antibodies to HTLV-I: activate lymphocytes in tropical spastic paraparesis. Ann Neurol 1988;23(Suppl):S196-S200
11. Itoyama Y, Minato S, Kira J, et al. Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy. Neurology 1988;28:1302-1307
12. Jacobson S, Shida H, McFarlin DE, et al. Circulating CD8+ cytotoxic T-lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 1990;348: 245-248
13. Maruyama M, Shibuya H, Harada H, et al. Evidence for aberrant activation of the interleukin 2 autocrine loop by HTLV-I encoded p40x and T3/T1 complex triggering. Cell 1987;48: 343-350
14. Tendler CL, Greenberg SJ, Blattner WA, et al. Transactivation of interleukin 2 and its receptor induces immune activation in human T lymphotropic virus type I-associated myelopathy: pathological implications and a rationale for immunotherapy. Proc Natl Acad Sci USA 1990;87:5218-5222
15. Gout O, Gessain A, Iba-Zizen M, et al. The effect of zidovudine on chronic myelopathy associated with HTLV-I. J Neurol 1991;238:108-109 (Letter)
16. Sheremata WA, Benedict D, Squilacote DC, et al. High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy. Neurology 1993;43:2125-2129
17. Osame M, Igata A, Matsumoto M, et al. HTLV-I associated myelopathy (HAM): treatment trials, retrospective survey, and clinical and laboratory findings. Hematol Rev 1990;37:271-284
18. Kira J, Fujihara K, Itoyama Y, et al. Leukoencephalopathy in HTLV-I associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy. J Neurol Sci 1991;106:41-49
19. Kuroda Y, Takashima H, Ikeda A, et al. Treatment of HTLV-I associated myelopathy with high-dose intravenous gamma-globulin. J Neurol 1991;238:309-314
20. Harrington WJ, Sheremata WA, Snodgrass SR, et al. Tropical spastic paraparesis/HTLV-I associated myelopathy (TSP/ HAM): treatment with an anabolic steroid Danazol. AIDS Res Hum Retrovirus 1991;7:1031-1034
21. Kataoka A, Imai H, Inayoshi S, Tsuda T. Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy. J Neurol Neurosurg Psychiatry 1993;56:1213-1216
22. Shibayama K, Nakamura T, Nagasato K, et al. Interferon-alpha treatment in HTLV-I-associated myelopathy: studies in clinical and immunological aspects. J Neurol Sci 1991;106:186-192
23. Matsuo H, Nakamura T, Tsujihata M, et al. Human T-lymphotropic virus type I (HTLV-I) associated myelopathy in Nagasaki: clinical features and treatment of 21 cases. Jpn J Med 1989;28:328-334
24. Junghans RP, Waldmann TA, Landolfi NF, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 1990;50:1495-1502
25. Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia. Blood 1993;82:1701-1712
26. Waldmann TA, Goldman CK, Bongiovanni KF, et al. Therapy of patients with human T-cell lymphotropic virus I-induced adult T-cell leukemia with anti-tac, a monoclonal antibody to the receptor for interleukin-2. Blood 1988;72:1805-1816
27. Vincenti F, Kirkman R, Light S, et al. Interleukin-2 receptor blockade with Daclizumab to prevent acute renal rejection in renal transplantation. N Engl J Med 1998;338:161-165
28. Scientific Group on ATLV-I Infections and Its Association Disease. Manila, Philippines: Office for the Western Pacific of the World Health Organization, March 1989
29. Hakimi J, Chizzonite R, Luke DR, et al. Reduced immunogenicity and improved pharmacokinetics of humanized anti-tac in cynomologous monkeys. J Immunol 1991;147:1352-1359
30. Fleisher TA. Phenotypic analysis of mononuclear leucocytes by flow cytometry. Immunol Allergy Clin North Am 1994;14: 225-240